Schrodinger (SDGR)
(Delayed Data from NSDQ)
$21.37 USD
-0.42 (-1.93%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $21.36 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SDGR 21.37 -0.42(-1.93%)
Will SDGR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SDGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SDGR
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
SDGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
Countdown to Schrodinger, Inc. (SDGR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Compared to Estimates, Schrodinger, Inc. (SDGR) Q3 Earnings: A Look at Key Metrics
Other News for SDGR
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
First Week of August 16th Options Trading For Schrodinger (SDGR)
Largest Clinical-Stage Biotech Drug Stocks Declined 6%